GlassScriptPhysician profile
Michael V Venanzi
NPI 1417038373
$1,847.25
in general payments reported to CMS, 2019-2025
23 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $400 · 2021: $537 · 2022: $267 · 2023: $165 · 2024: $95.44 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348 · Education: $71.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.77 |
| Education | $71.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $609.53 | 2020-2021 | |
| Abbvie INC. | $211.17 | 2019-2023 | Lo Loestrin Fe, Orilissa, Liletta |
| Mayne Pharma Commercial LLC | $131.17 | 2021-2025 | |
| Exact Sciences Corporation | $113.54 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $91.57 | 2019-2025 | Gardasil 9 |
| Myovant Sciences INC. | $85.80 | 2021-2022 | |
| Millicent US INC | $82.87 | 2021-2025 | |
| Exeltis, USA INC. | $81.98 | 2019-2025 | Slynd |
| Pfizer INC. | $70.22 | 2020-2023 | |
| Therapeuticsmd, INC. | $54.80 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $53.89 | 2021 | |
| Allergan, INC. | $42.69 | 2019-2020 | |
| Organon LLC | $36.40 | 2023-2024 | |
| Roche Diagnostics Corporation | $30.33 | 2019 | |
| Amgen INC. | $28.64 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $24.43 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.45 | 2022 | |
| Hologic Sales and Service, LLC | $18.96 | 2021 | |
| Davol INC. | $17.48 | 2021 | |
| Duchesnay USA Incorporated | $13.67 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.32 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.34 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Venanzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.